ArticleImmunology1998
Staphylococcal enterotoxin B inhibits the production of interleukin-4 in a human mast-cell line HMC-1.
Article in Immunology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 22 citations in OpenAlex.
- Mast Cells in Host Defense Against Cutaneous Staphylococcus aureus Infection.Immunology and cell biology · 2026Review
- A two-step activation mechanism enables mast cells to differentiate their response between extracellular and invasive enterobacterial infection.Nature communications · 2024Article
- Exploring the Role ofToxins · 2019Review
- Monoclonal antibodies protect from Staphylococcal Enterotoxin K (SEK) induced toxic shock and sepsis by USA300 Staphylococcus aureus.Virulence · 2017Article
- Article
- Staphylococcus aureus superantigens and airway disease.Current allergy and asthma reports · 2002Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Staphylococcal enterotoxins belong to the recently characterized group of immunocytotropic bacterial superantigens that are potent mitogens for human T cells. Superantigens are presented, but without intracellular processing, to T cells by monocyte/macrophages, Langerhans' cells and keratinocytes via the class II major histocompatibility complex (MHC) molecules. Superantigens have been demonstrated to act as potent inducers of several proinflammatory cytokines in the antigen-presenting cells such as interleukin-1 (IL-1) and tumour necrosis factor-alpha (TNF-alpha). As mast cells participate in the pathogenesis of several inflammatory skin disorders such as atopic dermatitis (AD), which is often aggravated by staphylococcal infections, we studied the effect of staphylococcal enterotoxin B (SEB) superantigen on the histamine release and IL-4 expression in a human mast-cell line (HMC-1). Incubation of SEB (50 micrograms/ml) with HMC-1 cells for 45 min, could not induce any histamine release. The HMC-1 cells were also stimulated with various concentrations of SEB (0, 1, 10, 20, 50 micrograms/ml) for 1, 2, 3 and 4 days. Clear dose-dependent inhibition of IL-4 protein production and release was observed on day 4 without any observed effect on cell viability. Compared with unstimulated HMC-1 cells, after 50 micrograms/ml SEB stimulation, the IL-4 mRNA levels decreased steadily in the 2, 6, 18 and 24 hr samples in repeated experiments as measured with the reverse transcription polymerase chain reaction (RT-PCR) method. In comparison, a biphasic decrease in TNF-alpha expression was found. Our results show that an human leukaemic mast cells, superantigen stimulation downregulates the production of IL-4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.